Who is the CEO of Surrozen, Inc.?

Mr. Craig C. Parker M.B.A. is a business executive who currently serves as the CEO of Surrozen, Inc..

What is the Revenue Growth of Surrozen, Inc.?

Revenue growth data for Surrozen, Inc. is currently unavailable.

What is Surrozen, Inc. operating Margin?

Surrozen, Inc. operating margin is -243.64% which shows how much profit SRZNW earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Surrozen, Inc. operate?

Surrozen, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Surrozen, Inc. revenue growth?

Revenue growth data for Surrozen, Inc. is currently unavailable.

Surrozen, Inc.

SRZNW•NASDAQ

Healthcare

Biotechnology

$0.02

$0.00(1.005%)

Surrozen, Inc. (SRZNW) Stock Overview

Explore Surrozen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for SRZNWStats details for SRZNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for SRZNWAnalyst Recommendations details for SRZNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.

CEO

Mr. Craig C. Parker M.B.A.

Employees

Headquarters

171 Oyster Point Boulevard, South San Francisco, CA

Founded

2021

Frequently Asked Questions

;